FDA Approved: VASCEPA — Supplemental Application (Amarin Pharma Inc.)

View source ↗

Summary

FDA approves a supplemental application for Vascepa (icosapent ethyl), expanding its labeling to address cardiovascular risk reduction in adults with elevated t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Diabetes Mellitus
• Hypertriglyceridemia

Drugs mentioned

• Vascepa (icosapent ethyl)

Snippet

SUPPL AP for VASCEPA (ICOSAPENT ETHYL)